Therapies targeting exogenous cholesterol uptake: New insights and controversies

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 95-100

  Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cholesterol absorption; FXR; LXR; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER G1; BILE ACID; BILE ACID SEQUESTRANT; CARRIER PROTEIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE 2; COLESEVELAM; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTANOL; PHYTOSTEROL; PROTEIN ABCG5; PROTEIN ABCG8; PROTEIN NPC1L1; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BILE ACID METABOLISM; CAROTID ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GALLBLADDER DISEASE; HUMAN; INTESTINE ABSORPTION; METABOLIC DISORDER; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; AZETIDINES; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; DRUG DISCOVERY; HUMANS; INTESTINAL ABSORPTION; METABOLIC DISEASES; MICE; MOLECULAR TARGETED THERAPY; SITOSTEROLS; STEROL O-ACYLTRANSFERASE;

EID: 79551517633     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0151-2     Document Type: Article

References (46)

1. HR Davis Jr SW Altmann 2009 Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter Biochim Biophys Acta 1791 679 83 1:CAS:528: DC%2BD1MXnt1GnsbY%3D 19272334
2. JM Brown L Yu 2009 Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8) Immunol Endocr Metab Agents Med Chem 9 18 29 1:CAS:528: DC%2BD1MXmvVWqs7s%3D 10.2174/187152209788009797 20174593
3. AE van der Velde G Brufau AK Groen 2010 Transintestinal cholesterol efflux Curr Opin Lipidol 21 167 71 10.1097/MOL.0b013e3283395e45 20410820
4. MH Davidson KC Maki DM Umporowicz KA Ingram MR Dicklin E Schaefer RW Lane JR McNamara JD Ribaya-Mercado G Perrone SJ Robins WC Franke 2001 Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women J Am Coll Nutr. 20 4 307 19 1:CAS:528:DC%2BD3MXmsVymurg%3D 11506058
5. Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 2005;96(1A):47D-50D.
6. RE Ostlund Jr JB McGill CM Zeng, et al. 2002 Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans Am J Physiol Endocrinol Metab 282 E911 6 1:CAS:528:DC%2BD38XivVels7o%3D 11882512
7. GW Meijer MAJJ Bressers WA de Groot M Rudrum 2003 Effect of structure and form on the ability of plant sterols to inhibit cholesterol absorption in hamsters Lipids 38 713 21 1:CAS:528:DC%2BD3sXntFCjs7g%3D 10.1007/s11745-003- 1119-4 14506834 (Pubitemid 37362263)
8. L Calpe-Berdiel JC Escola-Gil F Blanco-Vaca 2009 New insights into the molecular actions of plant sterols and stanols in colesterol metabolismo Atherosclerosis 203 18 31 1:CAS:528:DC%2BD1MXis1eqsbg%3D 10.1016/j. atherosclerosis.2008.06.026 18692849
9. J Plat JA Nicholes RP Mensink 2005 Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation J Lipid Res 46 2468 76 1:CAS:528:DC%2BD2MXhtF2iu7nO 10.1194/jlr.M500272-JLR200 16150823 (Pubitemid 41532535)
10. T Plosch JK Kruit VW Bloks, et al. 2006 Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the abcg5/8 transporter J Nutr 136 2135 40 16857831
11. L Calpe-Berdiel JC Escola-Gil F Blanco-Vaca 2007 Are LXR-regulated genes a major molecular target of plant sterols/stanols? Atherosclerosis 195 210 1 1:CAS:528:DC%2BD2sXhtF2hurzL 10.1016/j.atherosclerosis.2006.11.042 17222851 (Pubitemid 47561946)
12. AbuMweis SS, Barake R, Jones PJH. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52:doi: 10.3402/fnrv52i0.1811.
13. KE Berge K von Bergmann D Lutjohann, et al. 2002 Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism of ABCG5 and ABCG8 J Lipid Res 43 486 94 1:CAS:528:DC%2BD38XisVKmsrs%3D 11893785
14. MA Hallikainen ES Sarkkinen H Gylling AT Erkkila MI Uusitupa 2000 Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet Eur J Clin Nutr 54 715 25 1:CAS:528: DC%2BD3cXnsVCrsbg%3D 10.1038/sj.ejcn.1601083 11002384
15. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R,, for the Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-78.
16. AT Sane D Sinnet E Delvin M Bendayan V Marcil D Menard JF Beaulieu E Levy 2006 Localization and role of NPC1L1 in cholesterol absorption in human intestine J Lipid Res 47 2112 20 1:CAS:528:DC%2BD28XhtFCgsb3M 10.1194/jlr.M600174-JLR200 16829661 (Pubitemid 44936122)
17. D Gómez-Garre P Muñoz-Pacheco ML González-Rubio P Aragoncillo R Granados A Fernández-Cruz 2009 Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect Br J Pharmacol 156 1218 27 10.1111/j.1476-5381.2008.00091.x 19222481
18. BG Brown AJ Taylor 2008 Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 358 1504 7 1:CAS:528:DC%2BD1cXktlSgtbw%3D 10.1056/NEJMe0801608 18376002 (Pubitemid 351482746)
19. E Sehayek SL Hazen 2008 Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages Arterioscler Thromb Vasc Biol 28 1296 7 1:CAS:528: DC%2BD1cXmvFehsbc%3D 10.1161/ATVBAHA.108.165803 18420997
20. ME Greenberg JD Smith E Sehayek 2009 Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect Arterioscler Thromb Vasc Biol 29 1745 50 1:CAS:528:DC%2BD1MXht1ynu7bM 10.1161/ATVBAHA.109.194605 19661480
21. HR Davis LM Hoos G Tetzloff M Maquire L Zhu MP Graziano SW Altmann 2007 Deficiency of Niemann-Pick C1 Like 1 (NPC1L1) prevents atherosclerosis in apo E -/- mice Atheroscl Thromb Vasc Biol 27 841 9 1:CAS:528:DC%2BD2sXislCku78%3D 10.1161/01.ATV.0000257627.40486.46 (Pubitemid 46606715)
22. • Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. Erratum in: N Engl J Med 2008;358:1977. This is the study that raised doubts about the clinical benefit of ezetimibe.
23. MH Davidson 2008 Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications Clev Clin J Med 75 479 91 10.3949/ccjm.75.7.479
24. AJ Taylor TC Villines EJ Stanek PJ Devine L Griffen M Miller NJ Weissman M Turco 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 22 1:CAS:528:DC%2BD1MXhsFSnsLzP 10.1056/NEJMoa0907569 19915217
25. RM Califf Y Lokhnygina CP Cannon ME Stepanavage CH McCabe TA Musliner RC Pasternak MA Blazing RP Giugliano RA Harrington E Braunwald 2010 An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 705 9 10.1016/j.ahj.2010.03.004 20435175
26. TC Villines EJ Stanek PJ Devine M Turco M Miller NJ Weissman L Griffen AJ Taylor 2010 The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2721 6 10.1016/j.jacc.2010.03.017 20399059
27. SG Lakoski F Xu GL Vega SM Grundy M Chandalia C Lam RS Lowe ME Stepanavage TA Musliner JC Cohen HH Hobbs 2010 Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin J Clin Endocrinol Metab 95 800 9 1:CAS:528:DC%2BC3cXitVaisb4%3D 10.1210/jc.2009-1952 19965915
28. L Jakulj MN Vissers AK Groen BA Hutten D Lutjohann EP Veltri JJ Kastelein 2010 Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial J Lipid Res 51 755 62 1:CAS:528:DC%2BC3cXjslenur0%3D 10.1194/jlr.M001487 19828909
29. DC Chan GF Watts SK Gan EM Ooi PH Barrett 2010 Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 1134 9 1:CAS:528:DC%2BC3cXnsFyltrg%3D 10.2337/dc09-1765 20185740
30. M Enjoji K Machida M Kohjima M Kato K Kotoh K Matsunaga M Nakashima M Nakamuta 2010 NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease Lipids Health Dis 9 29 10.1186/1476-511X-9-29 20222991
31. S Zúñiga H Molina L Azocar L Amigo F Nervi F Pimentel N Jarufe M Arrese F Lammert JF Miquel 2008 Ezetimibe prevents cholesterol gallstone formation in mice Liver Int 28 935 47 10.1111/j.1478-3231.2008.01808.x 18783541 (Pubitemid 352044442)
32. SD Turley MW Herndon JM Dietschy 1994 Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster J Lipid Res 35 328 9 1:CAS:528:DyaK2cXhsFOqtLc%3D 8169536
33. A Mencarelli S Fiorucci 2010 FXR an emerging therapeutic target for the treatment of atherosclerosis J Cell Mol Med 14 79 92 1:CAS:528: DC%2BC3cXlt1Oru7Y%3D 10.1111/j.1582-4934.2009.00997.x 20041971
34. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Koshykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription visa a negative FXR response element. J Clin Invest 2002;109-961-71.
35. A Sirvent AJ Verhoeven H Jansen V Kosykh RJ Darteil DW Hum JC Fruchart B Staels 2004 Farnesoid X receptor represses hepatic lipase gene expression J Lipid Res 45 2110 5 1:CAS:528:DC%2BD2cXpsVSkt74%3D 10.1194/jlr.M400221-JLR200 15342685 (Pubitemid 40990906)
36. M Watanabe SM Houten L Wang A Moschetta DJ Mangelsdorf RA Heyman DD Moore J Auwerx 2004 Bile acids lower triglyceride levels via a pathway involving FXR, SHP and SREBP-1c J Clin Invest 113 1408 18 1:CAS:528:DC%2BD2cXktlCltro%3D 15146238
37. NY Kalaany DJ Mangelsdorf 2006 LXRs and FXR: The yin and yang of cholesterol and fat metabolism Annu Rev Physiol 68 159 91 1:CAS:528: DC%2BD28XksFWksrs%3D 10.1146/annurev.physiol.68.033104.152158 16460270
38. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006;84-276-94.
39. L Malerod M Sportstol LK Juvet SA Mousavi T Gloen T Berg N Roos W Eskild 2005 Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1 Biochem Biophys Res Commun 336 1096 1105 1:CAS:528:DC%2BD2MXhtVKisrjO 10.1016/j.bbrc.2005.08.237 16168958 (Pubitemid 41383435)
40. Y Zhang I Zanotti MP Reilly JM Glick GH Rothblat DJ Rader 2003 Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo Circulation 108 661 3 1:CAS:528: DC%2BD3sXmtVWitr0%3D 10.1161/01.CIR.0000086981.09834.E0 12900335 (Pubitemid 36999247)
41. X Wang HL Collins M Ranalletta IV Fuki JT Bilheimer GH Rothblat AR Tall DJ Rader 2007 Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo J Clin Invest 117 2216 24 1:CAS:528:DC%2BD2sXoslOns70%3D 10.1172/JCI32057 17657311 (Pubitemid 47219566)
42. Y Zhang JR Da Silva M Reilly JT Billheimer GH Rothblat DJ Rader 2005 Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo J Clin Invest 115 2870 4 1:CAS:528:DC%2BD2MXhtVygt7bL 10.1172/JCI25327 16200214 (Pubitemid 41434414)
43. H Herrema M Meissner TH van Dijk G Brufau R Boverhof MH Oosterveer DJ Reijngoud M Müller F Stellaard AK Groen F Kuipers 2010 Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice Hepatology. 51 3 806 16 1:CAS:528:DC%2BC3cXks1Sqsr4%3D 10.1002/hep.23408 19998408
44. A Mencarelli S Fiorucci 2010 FXR an emerging therapeutic target for the treatment of atherosclerosis J Cell Mol Med 14 1-2 79 92 1:CAS:528: DC%2BC3cXlt1Oru7Y%3D 10.1111/j.1582-4934.2009.00997.x 20041971
45. MH Davidson V Dittakavi A Bandari DJ Davidson KC Maki PV Subbaiah 2006 Colesevelam HC1 decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol-fed rabbits J Applied Res 6 4 13 1:CAS:528: DC%2BD28Xkt1KltLo%3D
46. Q Shang M Saumoy JJ Holst G Salen G Xu 2010 Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am J Physiol Gastrointest Liver Physiol 298 G419 24 1:CAS:528:DC%2BC3cXjsFGgt7g%3D 10.1152/ajpgi.00362.2009 20044510